BIOMAT Database Logo BIOMAT Database Logo

Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. 1992

A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

A total of 24 patients presenting with small-cell lung cancer either resistant to or relapsing within 3 months after first-line treatment were entered in a phase II study of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU). ACNU was given i.v. at a dose of 75 mg/m2 every 6 weeks. We observed a partial response of 7 months' duration in one patient and one case of stable disease that lasted for 6 months; all other subjects exhibited progressive disease. Two patients developed brain metastases during treatment. The toxicity of ACNU consisted mainly of bone marrow suppression, especially thrombocytopenia. At this dose and on this schedule, ACNU shows minimal activity as second-line treatment in small-cell lung cancer.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015376 Nimustine Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms. ACNU,NSC 245382
D018288 Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) Carcinoma, Oat Cell,Oat Cell Carcinoma,Small Cell Carcinoma,Carcinomas, Oat Cell,Carcinomas, Small Cell,Oat Cell Carcinomas,Small Cell Carcinomas

Related Publications

A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group.
January 1993, European journal of cancer (Oxford, England : 1990),
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.
January 1992, European journal of cancer (Oxford, England : 1990),
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group.
February 1989, British journal of cancer,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
October 1996, Seminars in oncology,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Treatment of small cell lung cancer. Recent experience of the EORTC Lung Cancer Cooperative Group.
January 1994, Anticancer research,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
November 1985, European journal of cancer & clinical oncology,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
March 2003, Annals of oncology : official journal of the European Society for Medical Oncology,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
February 2010, Investigational new drugs,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer.
October 2002, Cancer research and treatment,
A S Planting, and T A Splinter, and A Ardizzoni, and J Estapé, and G Giaccone, and A Kirkpatrick, and O Dalesio, and J G McVie
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
January 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!